The incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing and the emergence of extensively drug-resistant tuberculosis (XDR-TB) is a major challenge. Controlling resistance, reducing transmission and improving treatment outcomes in MDR/XDR-TB patients is reliant on susceptibility testing. Susceptibility testing using phenotypic methods is labour intensive and time-consuming. Alternative methods, such as molecular assays are easier to perform and have a rapid turn-around time. The World Health Organization (WHO) has endorsed the use of line probe assays (LPAs) for first and second line diagnostic screening of MDR/XDR-TB.
We compared the performance of LPAs to BACTEC MGIT 960 system for susceptibility testing of bacterial resistance to first-line drugs: rifampicin (RIF), isoniazid (INH), ethambutol (EMB), and second-line drugs ofloxacin (OFL) and kanamycin (KAN). One hundred (100) consecutive non-repeat Mycobacterium tuberculosis cultures, resistant to either INH or RIF or both, as identified by BACTEC MGIT 960 were tested. All isoniazid resistant cultures (n = 97) and RIF resistant cultures (n = 90) were processed with Genotype®MTBDRplus and Genotype®MTBDRsl line probe assays (LPAs). The agar proportion method was employed to further analyze discordant LPAs and the MGIT 960 isolates.
The Genotype ®MTBDRplus (version 2) sensitivity, specificity, PPV and NPV from culture isolates were as follows: RIF, 100%, 87.9, 58.3% and 100%; INH, 100%, 94.4%, 93.5% and 100%. The sensitivity, specificity PPV and NPV for Genotype ® MTBDRsl (version 1 and 2) from culture isolates were as follows: EMB, 60.0%, 89.2%, 68.2% and 85.3%; OFL, 100%, 91.4%, 56.2% and 100%; KAN, 100%, 97.7%, 60.0% and 100%. Line probe assay showed an excellent agreement (k = 0.93) for INH susceptibility testing when compared to MGIT 960 system while there was good agreement (k = 0.6–0.7) between both methods for RIF, OFL, KAN testing and moderate agreement for EMB (k = 0.5). A high RIF mono-resistance (MGIT 960 33/97 and LPA 43/97) was observed.
LPAs are an efficient and reliable rapid molecular DST assay for rapid susceptibility screening of MDR and XDR-TB. Using LPAs in high MDR/XDR burden countries allows for appropriate and timely treatment, which will reduce transmission rates, morbidity and improve treatment outcomes in patients.
World Health Organization 2016. Global Tuberculosis Report 2016. Geneva: World Health Organization; 2016.
Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century [State of the Art]. Int J Tuberc Lung Dis. 1999;3:564–81. PubMed
Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Underst Stat. 1983;32:307–17.
Ocheretina O, Escuyer VE, Mabou MM, Royal-Mardi G, Collins S, Vilbrun SC, et al. Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. PLoS One. 2014;9:90569. CrossRef
Yakrus MA, Driscoll J, Lentz AJ, Sikes D, Hartline D, Metchock B, Starks AM. Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States. J Clin Microbiol. 2014;52:1932–7. CrossRefPubMedPubMedCentral
Rukasha I, Said HM, Omar SV, Koornhof H, Dreyer AW, Musekiwa A, Moultrie H, Hoosen AA, Kaplan G, Fallows D, Nazir IN. Correlation of rpoB mutations with minimal inhibitory concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS endemic setting, South Africa. Front Microbiol. 2016;7:1947. CrossRefPubMedPubMedCentral
Tan Y, Hu Z, Zhao Y, Cai X, Luo C, Zou C. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol. 2012;50:81–5. CrossRefPubMedPubMedCentral
Kiraz N, Oz Y, Saglik I. Evaluation of the genotype MTBDR assay for detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. Ind J Med Microbiol. 2014;32:318–22. CrossRef
Coovadia YM, Mahomed S, Pillay M, Werner L, Mlisana K. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region. PLoS One. 2013;8:11e77712. CrossRef
Muller B, Chihota VN, Pillay M, Klopper M, Streicher EM, Coetzee G, Trollip A, Hayes C, Bosman ME, van Pittius NCG, Victor TC, Gagneux S, van Helden PD, Warren RM. Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa. PLoS One. 2013;8(8):e70919. CrossRefPubMedPubMedCentral
WHO (2008) Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement WHO.
Zeng X, Jinga W, Zhang Y, Duan H, Huang H, Chu N. Performance of the MTBDRsl Line probe assay for rapid detection of resistance to second-line anti-tuberculosis drugs and ethambutol in China. Diagn Microbiol Infect Dis. 2017;89:112–7.
Swaminatha S, Sundaramurthi JC. Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis. Tuberculosis. 2016;101:31–40. CrossRef
Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjo M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, Cirillo DM. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol. 2015;53:2961. CrossRefPubMedPubMedCentral
Mao X, Ke Z, Shi X, Liu S, Tang B, Wang J, Huang H. Diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol with genotype MTBDRsl assay: a meta-analysis. Ann Clin Lab Sci. 2015;45:533. PubMed
Meaza A, Kebede A, Yaregal Z, Dagne Z, Moga S, Yenew B, Diriba G, Molalign H, Tadesse M, Adisse D, Getahun M, Desta K. Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infect Dis. 2017;17:280. CrossRefPubMedPubMedCentral
- Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa
Nontuthuko E. Maningi
Lesibana A. Malinga
John F. Antiabong
Ruth M. Lekalakala
Nontombi M. Mbelle
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II